水杨酸盐通过诱导S期阻滞和损伤DNA修复增强CRM1抑制剂抗肿瘤活性
本研究探讨水杨酸盐能否增强CRM1抑制剂KPT-330(selinexor)的抗肿瘤活性。体外和体内实验显示,胆碱水杨酸盐联合低剂量KPT-330对高危血液恶性肿瘤和实体瘤有强效广谱活性,且对正常细胞和器官毒性低。机制上,联合治疗抑制CRM1、Rad51和胸苷酸合成酶表达,导致核输出抑制、DNA损伤修复受损、嘧啶合成减少、S期阻滞和凋亡。
要点
- 水杨酸盐可显著增强CRM1抑制剂抗肿瘤活性,并允许使用更低剂量selinexor。
- K+CS联合在血液恶性肿瘤中显示强效广谱活性且对正常细胞毒性低。
- 联合治疗抑制CRM1、Rad51和胸苷酸合成酶,诱导S期阻滞和凋亡。
核心结论
- 水杨酸盐通过诱导S期阻滞和损伤DNA修复增强CRM1抑制剂的抗肿瘤活性。
研究设计与样本
- 研究使用体外和体内实验,评估胆碱水杨酸盐联合低剂量KPT-330对高危血液恶性肿瘤和实体器官癌症的活性。
主要发现
- K+CS联合在高危血液恶性肿瘤和实体器官癌症的体外和体内模型中具有强效广谱活性。
- K+CS对非恶性细胞相比恶性细胞无毒性,且在小鼠中不诱导正常器官毒性。
- 与单用KPT-330相比,K+CS抑制CRM1、Rad51和胸苷酸合成酶蛋白表达,导致更有效抑制CRM1介导的核输出、损伤DNA修复、减少嘧啶合成、S期细胞周期阻滞和细胞凋亡。
- 添加聚(ADP-核糖)聚合酶抑制剂进一步增强K+CS的抗肿瘤效果。
临床怎么用
- 水杨酸盐联合低剂量selinexor可能为多种血液癌症提供新治疗选择,并可能减轻临床不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chromosome region maintenance protein 1 (CRM1) mediates protein export from the nucleus and is a new target for anticancer therapeutics. Broader application of KPT-330 (selinexor), a first-in-class CRM1 inhibitor recently approved for relapsed multiple myeloma and diffuse large B-cell lymphoma, have been limited by substantial toxicity. We discovered that salicylates markedly enhance the antitumor activity of CRM1 inhibitors by extending the mechanisms of action beyond CRM1 inhibition. Using salicylates in combination enables targeting of a range of blood cancers with a much lower dose of selinexor, thereby potentially mitigating prohibitive clinical adverse effects. Choline salicylate (CS) with low-dose KPT-330 (K+CS) had potent, broad activity across high-risk hematological malignancies and solid-organ cancers ex vivo and in vivo. The K+CS combination was not toxic to nonmalignant cells as compared with malignant cells and was safe without inducing toxicity to normal organs in mice. Mechanistically, compared with KPT-330 alone, K+CS suppresses the expression of CRM1, Rad51, and thymidylate synthase proteins, leading to more efficient inhibition of CRM1-mediated nuclear export, impairment of DNA-damage repair, reduced pyrimidine synthesis, cell-cycle arrest in S-phase, and cell apoptosis. Moreover, the addition of poly (ADP-ribose) polymerase inhibitors further potentiates the K+CS antitumor effect. K+CS represents a new class of therapy for multiple types of blood cancers and will stimulate future investigations to exploit DNA-damage repair and nucleocytoplasmic transport for cancer therapy in general.
引用
- Abeykoon JP, Wu X, Nowakowski KE, et al. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. Blood. 2021. PMID: 33507295. doi:10.1182/blood.2020009013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。